LB Pharmaceuticals Inc Common Stock(LBRX)

Biotechnology · New York, NY

$34.20-0.42 (-1.20%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:52:10.808Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:52:10.808Z.

Quote observation: 2026-10-06T16:50:12.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -94,790,000
Quote market capitalization: 980,841,867
Total debt · period ending 2026-06-30: 5,217,000
Cash · period ending 2026-06-30: 283,111,000

FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LBRX EBITDA Yield Metrics

EBITDA YIELD

N/A

LBRX Competitors' EBITDA Yield

LBRX

LB Pharmaceuticals Inc Common Stock

Current

Market Cap

$980.84M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGTX

MeiraGTx Holdings plc

vs LBRX

Market Cap

$980.23M

EBITDA Yield

20.70%

TTM Avg

16.68%

3Y Avg

16.68%

5Y Avg

16.68%

PCRX

Pacira BioSciences, Inc.

vs LBRX

Market Cap

$983.38M

EBITDA Yield

8.71%

TTM Avg

9.22%

3Y Avg

7.66%

5Y Avg

6.32%

AKTS

Aktis Oncology, Inc.

vs LBRX

Market Cap

$976.32M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRCT

PROCEPT BioRobotics Corporation

vs LBRX

Market Cap

$990.75M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs LBRX

Market Cap

$999.75M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SVRA

Savara Inc.

vs LBRX

Market Cap

$955.98M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs LBRX

Market Cap

$949.00M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPTX

Seaport Therapeutics, Inc. Common Stock

vs LBRX

Market Cap

$947.49M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs LBRX

Market Cap

$938.31M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
LB Pharmaceuticals Inc Common Stock (LBRX)	$980.84M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$980.23M	20.70%	16.68%	16.68%	16.68%
Pacira BioSciences, Inc. (PCRX)vs ›	$983.38M	8.71%	9.22%	7.66%	6.32%
Aktis Oncology, Inc. (AKTS)vs ›	$976.32M	N/A	N/A	N/A	N/A
PROCEPT BioRobotics Corporation (PRCT)vs ›	$990.75M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$999.75M	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$955.98M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$949.00M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$947.49M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$938.31M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

LBRX EBITDA Yield Metrics

LBRX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics